Financials in USD. Standardized financial statements.
A compact view of how Cyclerion Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.07M | $2.00M | $0 | $297,000 | $3.32M | $2.30M | $4.51M | $0 | $0 | $0 |
| Revenue Growth? | +3.7% | 0.0% | -100.0% | -91.1% | +44.6% | -49.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $5.58M | $0 | $56.41M | $95.14M | $1.53M | $1.75M | $2.17M |
| Gross Profit? | $2.07M | $2.00M | $0 | -$5.28M | $3.32M | -$54.12M | -$90.63M | -$1.53M | -$1.75M | -$2.17M |
| Gross Margin? | +100.0% | +100.0% | 0.0% | -1778.5% | +100.0% | -2357.1% | -2010.9% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $7.05M | $5.63M | $12.95M | $13.26M | $58.52M | $27.15M | $34.40M | $115.25M | $93.92M | $61.38M |
| Operating Income? | -$4.97M | -$3.63M | -$12.95M | -$18.54M | -$55.20M | -$81.27M | -$125.04M | -$115.25M | -$93.92M | -$63.55M |
| EBITDA? | -$4.97M | -$3.63M | -$9.58M | -$18.48M | -$53.84M | -$80.64M | -$122.34M | -$113.72M | -$92.18M | -$61.38M |
| Income Before Tax | -$3.53M | -$3.06M | -$12.59M | -$18.25M | -$51.65M | -$77.80M | -$123.01M | -$115.25M | -$93.92M | -$63.55M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$3.53M | -$3.06M | -$5.26M | -$44.08M | -$51.65M | -$77.80M | -$123.01M | -$115.25M | -$93.92M | -$63.55M |
| EPS? | $-1.09 | $-1.21 | $-8.99 | $-20.15 | $-26.40 | $-47.80 | $-88.37 | $-84.42 | $-68.80 | $-46.39 |
| Diluted EPS? | $-1.09 | $-1.21 | $-8.99 | $-20.15 | $-26.40 | $-47.80 | $-88.37 | $-84.42 | $-68.80 | $-46.39 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality